Interferon-γâDependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo
Purpose: To investigate the impact of interferon-γâmediated upregulation of major histocompatibility complex class I expression on tumor-specific T-cell cytotoxicity and T-cell trafficking into neuroblastoma tumors in vivo . Experimental Design: Restoration of major histocompatibility complex cla...
Gespeichert in:
Veröffentlicht in: | Clinical cancer research 2009-11, Vol.15 (21), p.6602 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose: To investigate the impact of interferon-γâmediated upregulation of major histocompatibility complex class I expression on
tumor-specific T-cell cytotoxicity and T-cell trafficking into neuroblastoma tumors in vivo .
Experimental Design: Restoration of major histocompatibility complex class I expression by interferon-γ treatment enhances killing of neuroblastoma
cells. To understand the potential of this approach in vivo , we developed a novel model of neuroblastoma in which NOD/ scid / IL2Rγ null immunodeficient mice are engrafted with both human T cells and tumor cells.
Results: Here, we show enhanced killing of neuroblastoma cells by patient-derived, tumor-specific T cells in vitro . In addition, interferon-γ treatment in vivo induces efficient upregulation of major histocompatibility complex class I expression on neuroblastoma tumor cells, and this
is accompanied by significantly enhanced infiltration of T cells into the tumor. In a pilot clinical trial in patients with
high-risk neuroblastoma, we similarly observed augmented T-cell trafficking into neuroblastoma nests in tumor biopsy specimens
obtained from patients after 5 days of systemic interferon-γ therapy.
Conclusions: Interferon-γ overcomes critical obstacles to the killing of human neuroblastoma cells by specific T cells. Together, these
findings provide a rationale for the further testing of interferon-γ as an approach for improving the efficacy of T cellâbased
therapies for neuroblastoma and other major histocompatibility complex class Iâdeficient malignancies. In addition, we describe
a model that may expedite the preclinical screening of approaches aimed at augmenting T-cell trafficking into human tumors.
(Clin Cancer Res 2009;15(21):6602â8) |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-09-0829 |